Indian pharma: Unethical practices, marketing rules under lens; new review body
Benchmarks Nifty22,600.00-87.66FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.69 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.25 % Invest NowEnter search…
Read report ↗